Bruno Chiarello
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Bruno Chiarello has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Massimo Bonacchi
Cardiac Surgery Unit, Department of Experimental and Clinical Medicine, University of Florence, 50121 Firenze, Italy
5 shared publications - Aleksander Dokollari
Cardiac Surgery Department, St. Boniface Hospital, University of Manitoba, Winnipeg, MB R2H 2A6, Canada
4 shared publications - Beatrice Bacchi
Division of Cardiac Surgery, St. Michael’s Hospital, University of Toronto, Toronto, ON M5G 2C4, Canada
3 shared publications - Francesco Cabrucci
Department of Cardiac Surgery Research, Lankenau Institute for Medical Research, Main Line Health, Wynnewood, PA 19096, USA
3 shared publications - Alan Ciardo
Cardiac Surgery F.U., Department of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy
1 shared publication Aleksander Dokollari
Department of Cardiac Surgery, Lankenau Institute for Medical Research, Main Line Health, Wynnewood, PA, USA
1 shared publication
Latest Publications
- Open Access
- 3 October 2026
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 13 (10) , 496
Sequential Arch-Tear Eligibility for Uncovered Aortic Arch Stent in Acute DeBakey Type I Aortic Dissection
Background: Because an uncovered arch scaffold does not provide a covered seal across an unresected arch tear, we evaluated a source-adjudicated sequential eligibility framework separating study-defined stop gates from residual-risk modifiers. Methods: We retrospectively analyzed 266 patients with acute DeBakey type I dissection treated by hemiarch repair alone (No. = 160) or hemiarch plus AMDS (No. = 106). Blinded preoperative CT-scan re-review validated Gate 1 (visible arch tear), and operative-report review confirmed Gate 2 (tear directly observed at open inspection). Supra-aortic false-lumen communication was assessed only after both gates were negative. Results: Sixty-nine patients (25.9%) passed both study-defined gates (AMDS = 32; hemiarch = 37). Twelve-month CT-scan was available in 45/69 (65.2%; AMDS 24/32, hemiarch 21/37). Among imaged patients, complete zone 2–3 false-lumen exclusion occurred in 20/24 (83.3%) after AMDS and 0/21 after hemiarch (risk difference +83.3 percentage points, 95% CI +58.7 to +93.3; p < 0.001). DANE occurred in 4/32 (12.5%) and 16/37 (43.2%), respectively (p = 0.007). Under the adverse opposing missingness scenario, the exclusion risk difference narrowed to +19.3 percentage points (95% CI −4.2 to +39.9; p = 0.148). Conclusions: These findings are hypothesis-generating and apply to a selected post hoc subgroup; treatment comparisons are non-causal. Prospective external validation of the study-defined hierarchy remains required.
- 3 October 2026
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 13 (10) , 496
Open AccessSequential Arch-Tear Eligibility for Uncovered Aortic Arch Stent in Acute DeBakey Type I Aortic Dissection
Background: Because an uncovered arch scaffold does not provide a covered seal across an unresected arch tear, we evaluated a source-adjudicated sequential eligibility framework separating study-defined stop gates from residual-risk modifiers. Methods: We retrospectively analyzed 266 patients with acute DeBakey type I dissection treated by hemiarch repair alone (No. = 160) or hemiarch plus AMDS (No. = 106). Blinded preoperative CT-scan re-review validated Gate 1 (visible arch tear), and operative-report review confirmed Gate 2 (tear directly observed at open inspection). Supra-aortic false-lumen communication was assessed only after both gates were negative. Results: Sixty-nine patients (25.9%) passed both study-defined gates (AMDS = 32; hemiarch = 37). Twelve-month CT-scan was available in 45/69 (65.2%; AMDS 24/32, hemiarch 21/37). Among imaged patients, complete zone 2–3 false-lumen exclusion occurred in 20/24 (83.3%) after AMDS and 0/21 after hemiarch (risk difference +83.3 percentage points, 95% CI +58.7 to +93.3; p < 0.001). DANE occurred in 4/32 (12.5%) and 16/37 (43.2%), respectively (p = 0.007). Under the adverse opposing missingness scenario, the exclusion risk difference narrowed to +19.3 percentage points (95% CI −4.2 to +39.9; p = 0.148). Conclusions: These findings are hypothesis-generating and apply to a selected post hoc subgroup; treatment comparisons are non-causal. Prospective external validation of the study-defined hierarchy remains required.
- 13 October 2025
- Published by European Association of Cardiothoracic Surgery (EACTS Publishing Ltd) in Multimedia Manual of Cardio-Thoracic Surgery
- Vol. 2025
Carbon fibre-enforced stabilization system for ministernotomy resynthesis
Sternal dehiscence incidence ranges from 0.2% to 5%]. Risk factors include obesity, advanced age, use of bilateral internal thoracic arteries, diabetes mellitus and chronic obstructive pulmonary disease [1]. Traditional techniques with steel wires have been associated with dehiscence rates of up to 11.8% [2]. Utilizing titanium plates, the incidence of sternal dehiscence has reduced to 1.5% [3]. The STERN FIX Sternal Stabilization System is a biocompatible carbon-fibre reinforced poly-ether-ether-ketone tool constituting two components, both with a curved arm that embraces the sternum at the level of an intercostal space and does not perforate the intercostal fascia, reducing the retrosternal bleeding [4]. The sternal closure is performed following five steps: sizing using a gauger (device available for sternal bone thicknesses between 9.5 and 17mm); marking the selected intercostal space bilaterally to allow the passage of the device; placement of both device parts; closure of the device; and cutting the excess segment. The sternal closure is complemented with cerclage wire. The first results are very satisfactory, with 0% sternal dehiscence at 6 months on 30 patients [5], comparable to those achieved by adopting the Robicsek technique [6]. We present a video tutorial case of ministernotomy closure using the STERN FIX system.
- 13 October 2025
- Published by European Association of Cardiothoracic Surgery (EACTS Publishing Ltd) in Multimedia Manual of Cardio-Thoracic Surgery
- Vol. 2025
Carbon fibre-enforced stabilization system for ministernotomy resynthesis
Sternal dehiscence incidence ranges from 0.2% to 5%]. Risk factors include obesity, advanced age, use of bilateral internal thoracic arteries, diabetes mellitus and chronic obstructive pulmonary disease [1]. Traditional techniques with steel wires have been associated with dehiscence rates of up to 11.8% [2]. Utilizing titanium plates, the incidence of sternal dehiscence has reduced to 1.5% [3]. The STERN FIX Sternal Stabilization System is a biocompatible carbon-fibre reinforced poly-ether-ether-ketone tool constituting two components, both with a curved arm that embraces the sternum at the level of an intercostal space and does not perforate the intercostal fascia, reducing the retrosternal bleeding [4]. The sternal closure is performed following five steps: sizing using a gauger (device available for sternal bone thicknesses between 9.5 and 17mm); marking the selected intercostal space bilaterally to allow the passage of the device; placement of both device parts; closure of the device; and cutting the excess segment. The sternal closure is complemented with cerclage wire. The first results are very satisfactory, with 0% sternal dehiscence at 6 months on 30 patients [5], comparable to those achieved by adopting the Robicsek technique [6]. We present a video tutorial case of ministernotomy closure using the STERN FIX system.
- 1 May 2024
- Published by SAGE Publications in Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery
- Vol. 19 (3) , 298-305
Impact of Pleural Integrity Preservation After Minimally Invasive Aortic Valve Surgery
Objective: While the benefits of minimally invasive aortic valve surgery compared with standard sternotomy have been widely described, the impact of preservation of pleural integrity (PPI) in minimally invasive surgery is still widely discussed. This study aims to define the role of PPI on postoperative and long-term outcomes after minimally invasive aortic valve replacement (MIAVR). Methods: All 2,430 consecutive patients undergoing MIAVR (ministernotomy or right anterior minithoracotomy) between 1997 and 2022 were included in the study. Patients were divided into 2 groups: patients with and without PPI. PPI was considered the maintenance of the pleura closed without the need for a chest tube insertion at the end of the surgical procedure. A propensity-matched analysis was used to compare the PPI and not-PPI groups. Results: After propensity matching, 848 patients were included in each group (PPI and not-PPI). The mean age was 70.21 versus 71.42 years, and the mean Society of Thoracic Surgeons predicted risk of mortality was 0.31% versus 0.30% in not-PPI versus PPI, respectively. The mean follow-up time was 147.4 months. Postoperatively, not-PPI versus PPI patients had a longer intensive care unit stay (9.7 vs 17.3 h, P < 0.001) and hospital length of stay (5.2 vs 8.9 days, P < 0.001). The rate of respiratory complications including the incidence of pneumothorax or subcutaneous emphysema, pulmonary atelectasis, and pleural effusion events requiring thoracentesis/drainage was significantly higher in not-PPI versus PPI. The 30-day all-cause mortality was higher in not-PPI versus PPI (0.029 vs 0.010, P = 0.003). Perioperative, short-term, and long-term all-cause mortality was significantly higher in the not-PPI group. Conclusions: PPI after MIAVR is associated with reduced incidence of postoperative complications, reduced lengths of stay, and improved overall survival compared with not-PPI. Therefore, a MIAVR tailored patient-procedure approach to maintaining the pleura integrity positively impacts short-term and long-term outcomes.
- 1 May 2024
- Published by SAGE Publications in Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery
- Vol. 19 (3) , 298-305
Impact of Pleural Integrity Preservation After Minimally Invasive Aortic Valve Surgery
Objective: While the benefits of minimally invasive aortic valve surgery compared with standard sternotomy have been widely described, the impact of preservation of pleural integrity (PPI) in minimally invasive surgery is still widely discussed. This study aims to define the role of PPI on postoperative and long-term outcomes after minimally invasive aortic valve replacement (MIAVR). Methods: All 2,430 consecutive patients undergoing MIAVR (ministernotomy or right anterior minithoracotomy) between 1997 and 2022 were included in the study. Patients were divided into 2 groups: patients with and without PPI. PPI was considered the maintenance of the pleura closed without the need for a chest tube insertion at the end of the surgical procedure. A propensity-matched analysis was used to compare the PPI and not-PPI groups. Results: After propensity matching, 848 patients were included in each group (PPI and not-PPI). The mean age was 70.21 versus 71.42 years, and the mean Society of Thoracic Surgeons predicted risk of mortality was 0.31% versus 0.30% in not-PPI versus PPI, respectively. The mean follow-up time was 147.4 months. Postoperatively, not-PPI versus PPI patients had a longer intensive care unit stay (9.7 vs 17.3 h, P < 0.001) and hospital length of stay (5.2 vs 8.9 days, P < 0.001). The rate of respiratory complications including the incidence of pneumothorax or subcutaneous emphysema, pulmonary atelectasis, and pleural effusion events requiring thoracentesis/drainage was significantly higher in not-PPI versus PPI. The 30-day all-cause mortality was higher in not-PPI versus PPI (0.029 vs 0.010, P = 0.003). Perioperative, short-term, and long-term all-cause mortality was significantly higher in the not-PPI group. Conclusions: PPI after MIAVR is associated with reduced incidence of postoperative complications, reduced lengths of stay, and improved overall survival compared with not-PPI. Therefore, a MIAVR tailored patient-procedure approach to maintaining the pleura integrity positively impacts short-term and long-term outcomes.
- Open Access
- 28 December 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (1) , 169
Severe Refractory Vasoplegic Shock Syndrome after OPCABG Successfully Treated with Hydroxycobalamin: A Case Report and Review of the Literature
Background: Vasoplegic shock syndrome (VSS) after an off-pump coronary artery bypass graft (OPCABG) is an extremely rare condition. Inotropic support is usually the first-line therapy, though it can precipitate several complications or be ineffective. We report the first case of severe refractory VSS after OPCABG successfully treated with hydroxycobalamin. Methods: A 77-year-old gentleman underwent OPCABG for three vessels coronary artery disease. Preoperative LV ejection fraction was 28%, and the patient before surgery started sacubitril/valsartan titrated, then, at the highest dose. Surgery was uneventful and, by the end of the procedure, TEE showed improved biventricular contractility. Results: The patient was transferred to the ICU without inotropic support, but soon developed hypotension. TEE ruled out pericardial tamponade and confirmed fair contractility. Norepinephrine was titrated to a medium-high dose, vasopressin was started and a Swan-Ganz catheter was placed. SVR was 480 dyn·s·cm−5. Despite aggressive pharmacologic treatment (including methylprednisolone and methylene blue), no improvements were noticed. Ten grams of hydroxycobalamin were administered. One hour later, hemodynamic status re-assessment showed SVR > 800 dyn·s·cm−5. Afterward, vasopressors were gradually reduced. Conclusions: Our case demonstrated the importance of adequate early treatment in VSS after OPCABG. This case report shows, for the first time, that hydroxycobalamin was effectively used to restore homeostasis.
- 28 December 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (1) , 169
Open AccessSevere Refractory Vasoplegic Shock Syndrome after OPCABG Successfully Treated with Hydroxycobalamin: A Case Report and Review of the Literature
Background: Vasoplegic shock syndrome (VSS) after an off-pump coronary artery bypass graft (OPCABG) is an extremely rare condition. Inotropic support is usually the first-line therapy, though it can precipitate several complications or be ineffective. We report the first case of severe refractory VSS after OPCABG successfully treated with hydroxycobalamin. Methods: A 77-year-old gentleman underwent OPCABG for three vessels coronary artery disease. Preoperative LV ejection fraction was 28%, and the patient before surgery started sacubitril/valsartan titrated, then, at the highest dose. Surgery was uneventful and, by the end of the procedure, TEE showed improved biventricular contractility. Results: The patient was transferred to the ICU without inotropic support, but soon developed hypotension. TEE ruled out pericardial tamponade and confirmed fair contractility. Norepinephrine was titrated to a medium-high dose, vasopressin was started and a Swan-Ganz catheter was placed. SVR was 480 dyn·s·cm−5. Despite aggressive pharmacologic treatment (including methylprednisolone and methylene blue), no improvements were noticed. Ten grams of hydroxycobalamin were administered. One hour later, hemodynamic status re-assessment showed SVR > 800 dyn·s·cm−5. Afterward, vasopressors were gradually reduced. Conclusions: Our case demonstrated the importance of adequate early treatment in VSS after OPCABG. This case report shows, for the first time, that hydroxycobalamin was effectively used to restore homeostasis.
- Open Access
- 14 November 2023
- Published by MDPI AG in Preprints.org
Severe Refractory Vasoplegic Shock Syndrome After OPCABG: Our Experience and Review of Literature
Background: Vasoplegic shock syndrome(VSS) after an off-pump coronary artery bypass graft (OPCABG) is an extremely rare condition. Inotropic support is usually the first-line therapy though it can precipitate several complications or be ineffective. We report the first case of severe refractory VSS after OPCABG successfully treated with hydroxycobalamin. Methods: A 77-year-old gentleman underwent OPCABG for three vessels coronary artery disease. Preoperative LV ejection fraction was 28%, and the patient before surgery started sacubi-tril/valsartan titrated, then, to the highest dose. Surgery was uneventful and, by the end of the procedure, TEE showed improved biventricular contractility. Results: The patient was transferred to the ICU without inotropic support but he developed soon hypotension. TEE ruled out pericardial tamponade and confirmed fair contractility. Norepineph-rine was titrated to a medium-high dose, vasopressin was started and a Swan-Ganz catheter was placed. SVR was 480 dyn·s·cm−5. Despite aggressive pharmacologic treatment (including Methylprednisolone and Methylene blue), no improvements were noticed. 10 g of hydroxycobalamin were administered. One hour later hemodynamic status re-assessment showed SVR > 800 dyn·s·cm−5. Afterward, vasopressors were gradually reduced. Conclusions: Our case demonstrated the importance of adequate early treatment in VSS after OPCABG. For the first time, hydroxycobalamin was effectively used to restore homeostasis.
- 14 November 2023
- Published by MDPI AG in Preprints.org
Open AccessSevere Refractory Vasoplegic Shock Syndrome After OPCABG: Our Experience and Review of Literature
Background: Vasoplegic shock syndrome(VSS) after an off-pump coronary artery bypass graft (OPCABG) is an extremely rare condition. Inotropic support is usually the first-line therapy though it can precipitate several complications or be ineffective. We report the first case of severe refractory VSS after OPCABG successfully treated with hydroxycobalamin. Methods: A 77-year-old gentleman underwent OPCABG for three vessels coronary artery disease. Preoperative LV ejection fraction was 28%, and the patient before surgery started sacubi-tril/valsartan titrated, then, to the highest dose. Surgery was uneventful and, by the end of the procedure, TEE showed improved biventricular contractility. Results: The patient was transferred to the ICU without inotropic support but he developed soon hypotension. TEE ruled out pericardial tamponade and confirmed fair contractility. Norepineph-rine was titrated to a medium-high dose, vasopressin was started and a Swan-Ganz catheter was placed. SVR was 480 dyn·s·cm−5. Despite aggressive pharmacologic treatment (including Methylprednisolone and Methylene blue), no improvements were noticed. 10 g of hydroxycobalamin were administered. One hour later hemodynamic status re-assessment showed SVR > 800 dyn·s·cm−5. Afterward, vasopressors were gradually reduced. Conclusions: Our case demonstrated the importance of adequate early treatment in VSS after OPCABG. For the first time, hydroxycobalamin was effectively used to restore homeostasis.
- Open Access
- 16 August 2023
- Published by MDPI AG in Preprints.org
Long-Term Outcomes in Patients Undergoing Thoracic Endovascular Aortic Repair. Single Center Experience
Background: To analyze long-term outcomes in patients undergoing thoracic endovascular aortic repair (TEVAR). Methods: All consecutive 97 patients undergoing TEVAR between September 2014 and September 2022 were included in the study. Primary outcome was long-term incidence of overall death and major adverse cardiovascular and cerebrovascular events (MACCE). Results: Mean age was 70.4 years, and 22(23.2%) had cerebrovascular disease (CBVD). A total of 49(51.6%) of patients had prior cardiac surgery intervention and 8(8.5%) had prior aortic valve replacement. Twenty-eight patients(28.8%) presented with aortic dissection, 60(61.8%) had aortic aneurysm, 4(4.1%) had intramural hematoma, and 5(5.1%) had other presentations. An emergent procedure was performed in 6(6.2%) patients, an urgent procedure in 37(38.1%) patients and 54(55.7%) patients had an elective procedure. Intraoperatively, 78.3% had percutaneous TEVAR, 5.1% had ministernotomy TEVAR, while 10.3% had concomitant full sternotomy TEVAR repair. Hospital mortality was 7 patients(7.2%). At 8-years follow-up, 76% were alive, 25.8% had MACCE, 21.6% were diagnosed with endoleaks(13 patients type II and 2 patients type 1) while 10.3% un-derwent repeat intervention. Conclusions: This single center experience in patients undergoing TEVAR evidenced good short and long-term survival and MACCE. Nonetheless, almost half of the patients underwent an ur-gent/emergent procedure, clinical results were favourable for TEVAR.
- 16 August 2023
- Published by MDPI AG in Preprints.org
Open AccessLong-Term Outcomes in Patients Undergoing Thoracic Endovascular Aortic Repair. Single Center Experience
Background: To analyze long-term outcomes in patients undergoing thoracic endovascular aortic repair (TEVAR). Methods: All consecutive 97 patients undergoing TEVAR between September 2014 and September 2022 were included in the study. Primary outcome was long-term incidence of overall death and major adverse cardiovascular and cerebrovascular events (MACCE). Results: Mean age was 70.4 years, and 22(23.2%) had cerebrovascular disease (CBVD). A total of 49(51.6%) of patients had prior cardiac surgery intervention and 8(8.5%) had prior aortic valve replacement. Twenty-eight patients(28.8%) presented with aortic dissection, 60(61.8%) had aortic aneurysm, 4(4.1%) had intramural hematoma, and 5(5.1%) had other presentations. An emergent procedure was performed in 6(6.2%) patients, an urgent procedure in 37(38.1%) patients and 54(55.7%) patients had an elective procedure. Intraoperatively, 78.3% had percutaneous TEVAR, 5.1% had ministernotomy TEVAR, while 10.3% had concomitant full sternotomy TEVAR repair. Hospital mortality was 7 patients(7.2%). At 8-years follow-up, 76% were alive, 25.8% had MACCE, 21.6% were diagnosed with endoleaks(13 patients type II and 2 patients type 1) while 10.3% un-derwent repeat intervention. Conclusions: This single center experience in patients undergoing TEVAR evidenced good short and long-term survival and MACCE. Nonetheless, almost half of the patients underwent an ur-gent/emergent procedure, clinical results were favourable for TEVAR.